1Rimer BK 徐从高等（译）.肿瘤筛查.癌－肿瘤学原理和实践[M].济南:山东科技出版社,2001.653-667.
2Wu W, Tang X, Hu W, et al. Identification and validation of metastasis -associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis, 2002,19 : 319-326.
3Alaiya A, Mohanna MA, Linder S. Clinical Cancer Proteomics: Promises and Pitfalls. J Proteome Res, 2005, 4:1213- 1222.
4Celis JE, Kruhoffer M, Gromova I, et al. Gene expression profiling: monitoring transcription and translation products using DNA micmarraysand proteomics. FEBS Lett, 2000, 480:2-16.
5Giltnane J M, Rimm DL. Technology Insight: identification of biomarkers with tissue microarray technology. Nat Clin Prac Oncol, 2004, 1 :104-111.
6Chen R, Pan S, Brentnall TA, et al. Proteomic profiling of pancreatic cancer for biomarker discovery. Mol Cell Proteomics, 2005, 4: 523-531.
8Issaq HJ, Conrads TP, Prieto A, et al. SELDI-TOF-MS for diagnostic proteomics. Anal Chem, 2003, 75 : 148A-155A.
9Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool-Opportunites and potential limitations, Mol Cell Proteomics,2004,3 : 367-378.
10Srinivas PR, Verma M, Zhao Y, et al. Proteomics for cancer biomarker discovery. Clin Chem, 2002, 48:1160-1169.
7Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology [J] . JClin Oncol, 2001, 19 (6) : 1865-1878.
8Molina R, Jo J, Filella X, et al. C-erb B-2 oncoprotein, CEA and CA153 in patients with breast cancer: prognostic value [J] . Breast CancerRes Treat, 1998, 51 (2) : 109-119.
9Robertson DM, Pruysers E, Jobling T. Inhibin as a diagnostic marker for ovarian cancer [J] . Cancer Lett, 2007, 249 (1) : 14-17.
